Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity

(2009) P. C.C. Liu et al.   CLINICAL CANCER RESEARCH

Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy

(2008) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Prevalence of polycythemia vera and essential thrombocythemia

(2008) Xiaomei Ma et al.   AMERICAN JOURNAL OF HEMATOLOGY

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

(2008) P. A. Beer et al.   BLOOD

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

(2008) R Chaligné et al.   LEUKEMIA